KYMR
Kymera Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.56
P/S
177.59
EV/EBITDA
-22.12
DCF Value
$0.35
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-891.3%
Net Margin
-794.4%
ROE
-29.1%
ROA
-17.9%
ROIC
-20.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.9M | $-87.0M | $-0.98 |
| FY 2025 | $39.2M | $-311.4M | $-3.69 |
| Q3 2025 | $2.8M | $-82.2M | $-0.94 |
| Q2 2025 | $11.5M | $-76.6M | $-0.95 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.29
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.